Regulus Therapeutics IPO: The biopharmaceutical company has filed an $57.50 million initial public offering application filing to the U.S. SEC (Securities and Exchange Commission) on August 17, 2012. Regulus Therapeutics intends to trade its common stock publicly on The NASDAQ Global Market under the “RGLS” symbol.
Regulus Therapeutics Inc., is a biopharmaceutical company formed in 2007 and engaged in the discovery and development of first-in-class drugs that target microRNAs to treat a broad range of diseases. The company is eligible to receive up to approximately $1.7 billion in milestone payments upon successful commercialization of microRNA therapeutics for eleven programs contemplated by their agreements.
Net proceeds of Regulus Therapeutics IPO and the concurrent private placement for preclinical and clinical development of its initial microRNA development candidates, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and other general corporate purposes as well as to in-license, acquire or invest in complementary microRNA businesses, technologies, products or assets.
Lazard Capital Markets is acting as book-running manager and as representative of the underwriters of Regulus Therapeutics IPO. Cowen and Company, BMO Capital Markets, Needham & Company and Wedbush Secutities are also working as underwriters for the public coffering.
Regulus Therapeutics IPO